UK Markets closed

Allarity Therapeutics, Inc. (ALLR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.0500+0.4100 (+25.00%)
At close: 04:00PM EDT
2.3000 +0.25 (+12.20%)
After hours: 05:51PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.6400
Open1.6500
Bid2.0400 x 1200
Ask2.2000 x 1000
Day's range1.6500 - 2.4000
52-week range1.1000 - 18.2000
Volume702,245
Avg. volume100,808
Market cap16.555M
Beta (5Y monthly)-0.00
PE ratio (TTM)N/A
EPS (TTM)-0.0570
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Correction Notice to Press Release Announcing Financial Results For the Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

    Cambridge, MA U.S.A. (May 18, 2022) — Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced today that its press release issued under the headline “Allarity Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update” on May 16, 2022, included a typographical error in the section titled “Full Year 2021 and Recent Highlights”, describing the size of the debt cancellation which should have read “$971 thousand” instead of “$971 million.” The corrected par

  • Globe Newswire

    Allarity Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

    Cambridge, MA U.S.A. (May 16, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today reported financial results for the fourth quarter and year ended December 31, 2021, and provided a corporate update. “2021 was a momentous year for Allarity Therapeutics,” said Steve Carchedi, President and Chief Executive Officer. “

  • Globe Newswire

    Allarity Therapeutics Provides Update on Dovitinib Program

    FOR IMMEDIATE RELEASE Allarity has requested a Type C meeting with the FDA to discuss potential clinical paths to support approval of dovitinib in view of the regulatory agency’s recent Refusal to File letters for the Company’s NDA and related PMA Allarity intends to announce the results of the Type C meeting and its plans for further advancing dovitinib and its DRP®-Dovitinib companion diagnostic before end of Q3 2022 Cambridge, MA U.S.A. (March 15, 2022) — Allarity Therapeutics, Inc. (“Allarit